{"id":2006,"date":"2022-03-25T23:46:42","date_gmt":"2022-03-25T23:46:42","guid":{"rendered":"https:\/\/linksus.net\/thursday-brings-more-good-news-for-the-imugene-asximu-share-price-the-motley-fool-australia\/"},"modified":"2022-03-25T23:46:42","modified_gmt":"2022-03-25T23:46:42","slug":"thursday-brings-more-good-news-for-the-imugene-asximu-share-price-the-motley-fool-australia","status":"publish","type":"post","link":"https:\/\/linksus2.linksus.net\/index.php\/2022\/03\/25\/thursday-brings-more-good-news-for-the-imugene-asximu-share-price-the-motley-fool-australia\/","title":{"rendered":"Thursday brings more good news for the Imugene (ASX:IMU) share price – The Motley Fool Australia"},"content":{"rendered":"

ASX 200<\/a>
|<\/span>
A<\/a>
B<\/a>
C<\/a>
D<\/a>
E<\/a>
F<\/a>
G<\/a>
H<\/a>
I<\/a>
J<\/a>
L<\/a>
M<\/a>
N<\/a>
O<\/a>
P<\/a>
Q<\/a>
R<\/a>
S<\/a>
T<\/a>
U<\/a>
V<\/a>
W<\/a>
X<\/a>
TO MAKE THE WORLD
SMARTER, HAPPIER, AND RICHER.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
What’s driving Imugene shares higher today?
Image source: Getty Images
The Imugene Limited<\/strong> (ASX: IMU)<\/a> share price is on the move today. This comes after the company announced an update on its phase 1 clinical trial of its oncolytic virotherapy candidate, Checkvacc.
Checkvacc is a novel treatment currently being tested to kill tumour cells and activate the immune system against cancer cells.
During early afternoon trade, the immuno-oncology company\u2019s shares are up 2.63% to 29.3 cents.
The Imugene share price is firmly in the green after providing investors with a positive update.
In its release, Imugene advised it will proceed to the second dose cohort<\/a> in the Checkvacc phase I clinical trial.
The study is being conducted at the City of Hope, a world-renowned cancer treatment and research centre near Los Angeles.
Imugene stated that Checkvacc was deemed to be safe from the Protocol Management Team.
Specifically, no dose-limiting toxicities (DLTs) and no serious adverse reactions were observed from the first cohort of patients. They were administered with the lowest dose of Checkvacc as monotherapy during the initial study.
The current trial design will involve a dose escalation, followed by an expansion to 12 patients at the final dose. This will then be recommended for a phase 2 dose (RP2D).
The trial is anticipated to run for 24 months and is funded from existing budgets and resources.
Imugene managing director and CEO Leslie Chong commented:
We are pleased with the results that we have seen so far with no observed toxicity with early encouraging results in oncolytic virus infection and replication in the TNBC tumours.
\u2026The Protocol Management Team for the study reviewed the first low dose cohort of patient\u2019s data and has recommended to proceed to the next dose escalation due to safety and tolerability.
Over the past 12 months, the Imugene share price has gained more than 154%. A sharp contrast when looking at year to date, with the latter down 27%.
The company\u2019s shares touched a 52-week high of 62.5 cents in November 2021, before travelling on a downhill trend.
Based on today\u2019s price, Imugene presides a market capitalisation<\/a> of roughly $1.71 billion.
Before you consider Imugene, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.
The online investing service he\u2019s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks<\/a>
*Returns as of January 13th 2022
Motley Fool<\/a> contributor Aaron Teboneras<\/a> has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy<\/a>. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.<\/em>
View All<\/a>
In this FREE STOCK REPORT<\/b>, Scott Phillips, and his team at Motley Fool\u2019s Share Advisor have released a special free report, detailing 5 ASX stocks that they think could be fantastic stocks to own as investors prepare for their retirement.
Sign Up for Take Stock<\/a><\/strong>
Investment news, stock ideas, and more, straight to your inbox.
Get Started Investing<\/a><\/strong>
You can do it. Learn about investing with our Investing Education hub.
Win at Retirement<\/a><\/strong>
Our latest articles and strategies for the post-work life you want.
Listen to Our Podcast<\/a><\/strong>
Hear our experts take on shares, the market & how to invest.
Join Our Premium Community<\/a><\/strong>
Join our flagship membership service, Share Advisor<\/em>.
To make the world Smarter, Happier, And Richer
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show and premium investing services. The Motley Fool launched its Australian presence in 2011, and since then has grown to reach over 1 million Australians.
Read more about us ><\/a>
\"\"
This Service provides only general, and not personalised financial advice, and has not taken your personal circumstances into account. The Motley Fool Australia operates under AFSL 400691. For more information please see our Financial Services Guide<\/a>. Please remember that investments can go up and down. Past performance is not necessarily indicative of future returns. The Motley Fool Australia does not guarantee the performance of, or returns on any investment.
\u00a9 2010 – 2021 The Motley Fool Australia Pty Ltd. All rights reserved.
ACN: 146 988 052
Australian Financial Services Licence (AFSL): 400691
The Motley Fool Australia, PO Box 104, Isle of Capri, Qld 4217
Contact Details:
<\/strong>Phone: (03) 8592 4841
Email: [email protected]<\/span><\/a>
Our friendly customer service team will happily get back to you as soon as they can.<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ASX 200 | A B C D E F G H I J L M N O P Q R S T U V W XTO MAKE THE WORLD SMARTER, HAPPIER, AND RICHER.Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, […]<\/p>\n","protected":false},"author":869,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/2006"}],"collection":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/users\/869"}],"replies":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/comments?post=2006"}],"version-history":[{"count":0,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/2006\/revisions"}],"wp:attachment":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/media?parent=2006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/categories?post=2006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/tags?post=2006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}